Ocugen announced that dosing is complete in the first cohort of its Phase 1/2 ArMaDa clinical trial for OCU410, a modifier gene therapy candidate being developed for geographic atrophy, an advanced stage of dry age related macular degeneration. GA affects approximately 1 million people in the United States alone. Up to 13 leading retinal surgery centers across the United States are participating in the ArMaDa clinical trial. The enrollment in the first cohort is now complete and 3 subjects received 200microL single subretinal administration of the low dose of OCU410.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OCGN:
- Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410
- Ocugen to Present at Investing in Cures Summit
- Ocugen announces availability of Clinical Showcase webcast
- Ocugen Clinical Showcase Webcast Now Available
- Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit
